Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing ...

Please provide your email address to receive an email when new articles are posted on . The FDA plans to reduce and potentially replace animal testing for developing monoclonal antibody therapies and ...

In a roadmap to change animal testing requirements for INDs, the U.S. FDA said its new approach will improve drug safety, hasten the evaluation process, and lower costs for companies and patients.

Organoids, organs-on-a-chip, and machine learning technologies have improved dramatically in recent years, but have they come far enough to replace animal research? Additionally, despite attempts to ...

The FDA is moving away from requiring animal models for investigational new drug (IND) applications for new monoclonal antibodies and some other drug candidates. Animal testing will be "reduced, ...

As excitement around animal testing alternatives reaches a fever pitch, Charles River Laboratories is making a move to strengthen its development of new approach methodologies (NAMs) that can ...